Zovighian Bernard J

CEO Bernard Zovighian sells $4.9M in EW shares in multi-transaction filing; 11th open-market sale in 36 months, part of planned equity dispositions.

Bernard Zovighian, Edwards Lifesciences' CEO, executed a significant multi-leg equity transaction disposing of roughly $4.9 million in stock across several sales and gifts over two days in May. This marks his 10th and 11th open-market sales in the past three years—a consistent pattern of selling rather than buying, with only one prior open-market purchase recorded. The stock is trading well below its 52-week high, yet Zovighian chose to sell into this weakness rather than accumulate. His prior five sales at this ticker showed mixed timing results—four were poorly-timed exits where the stock rose afterward, and one was well-timed as shares declined—suggesting his sales have not historically caught major downturns. The company itself remains profitable with growing revenues, trading at a moderate valuation, so the sales do not appear to be driven by fundamental deterioration. The combination of his heavy reliance on equity dispositions over acquisitions, the current sale size relative to his holdings, and the weak price position raises questions about whether this represents ordinary portfolio management or a signal worth deeper investigation.

CEO Bernard J Zovighian sold 22,430 shares for $1,719,741.31; holdings down 66.1% to 11,516 shares

CEO Bernard J Zovighian executed 2 separate sales totaling 22,430 shares for $1,719,741.31 on 2026-02-12, reducing his holdings by 66.1% from 33,946 shares to 11,516 shares. The blended average sale price of $76.67 occurred against a backdrop of near-term weakness: the stock is trading at $75.87, down 8.7% over 30 days and 12.1% over 90 days from its 52-week high of $86.94. At the same ticker, Zovighian's prior 5 trades show mixed outcomes: only 1 of 3 prior sells with measurable 90-day returns were well-timed (sold before decline), and his most recent two sales on 2025-12-10 and 2025-12-08 have post-sale returns of +2.0% and -0.4% respectively, suggesting the stock has not retreated sharply following those prior exits. The large reduction in CEO ownership warrants attention given the stock's recent underperformance relative to its 52-week high.

CEO Zovighian sold 25,350 shares (74.7% of holdings) for $2,153,373.46 in 2 transactions

Bernard J Zovighian, CEO of Edwards Lifesciences, executed 2 separate sales totaling 25,350 shares for $2,153,373.46 ($2.2M) on December 8–10, 2025, reducing his holdings by 74.7% from 33,946 to 8,596 shares. At blended average price $84.95, the sales occurred near the 52-week high of $86.82, within 3.3% of peak valuation. His prior open-market history at this ticker shows limited timing success: only 1 of 4 trades (25%) delivered well-timed outcomes at the 90-day mark, with his recent June and May 2025 sells followed by positive 90-day returns (+5.2% in both cases), indicating he sold before subsequent gains rather than before declines. The company faces headwinds (annual revenue growth of -9.4%, P/E of 35.56) that merit investor attention to whether concentrated insider reduction signals strategic repositioning or liquidity needs.

CEO Bernard J Zovighian sold 17.1K shares for $1.3M at $77.21–$77.32; -66.5% of pre-transaction holdings

CEO Bernard J Zovighian sold 2 separate tranches totaling 17,066 shares for $1,317,836.50 between 2025-05-30 and 2025-06-03, reducing his stake to 8,596 shares post-transaction (-66.5% vs pre-transaction holdings of 25,662). The blended average sale price of $77.22 is notably close to his actual transaction prices ($77.21 and $77.32), well above the 52-week low of $59.70 but 17.1% below the 52-week high of $93.78. His prior sale at EW on 2024-05-30 proved well-timed, with the stock declining 21.7% over 90 days after that transaction. The current filing represents a substantial reduction of his direct equity stake at a time when Edwards Lifesciences is reporting annual revenue decline of -9.4% (latest FY vs prior FY) and a relatively modest P/E of 10.90, though the stock has recovered 6.7% over the past 90 days from its lower point.